The lead molecule arising from our Fatty Acid Amide Hydrolase research programme, V158866 completed a phase II study in spinal cord injury patients in August 2015. It is now available for partnering.
- Generated from in-house research programme
- Potentially profound analgesic response
- Effective in pre-clinical pain models
May cause powerful analgesic response
Since endocannabinoids are only produced on demand, it may be that FAAH inhibitors, such as V158866, can selectively increase the local levels of neurotransmitter in tissues. This could deliver a powerful analgesic and anti-inflammatory response, without the side effects that more widespread cannabinoid receptor activation can generate.
Leading players in the pharmaceutical industry are paying particular interest to FAAH inhibitor molecules, with a number of them currently in development by the major companies. Additional possible indications for the class include the treatment of anxiety and depression.
- Carageenan-induced thermal hyperalgesia
- Carageenan-induced inflammation
- Mono-iodoacetate model of osteoarthritis
- Chronic constriction injury model of neuropathic pain
It has no significant effect on locomotor function in pre-clinical models, even at high doses.
A range of pre-clinical safety and pharmacokinetic studies were conducted on V158866.
In August 2015, the Company announced results from a Phase II POC study in which the programme was being investigated in patients with neurophathic pain as a result of spinal cord injury. Although the dosing of V158866 resulted in elevated endocannabanoid levels, on an intent-to-treat basis, the study failed to meet its pain reduction primary endpoint. Treatment did show a trend towards efficacy on a per protocol basis and was generally well tolerated.
We do not plan to make any further investment in this programme and seek to realise its potential value through partnering.
We do not plan to make any further investment in this programme and seek to realise its potential value through partnering